RESTORE: Once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates
The second nightly IR oxybate dose presents significant treatment burdens and adherence concerns. Participants overwhelmingly preferred the once-nightly dosing regimen of ON-SXB.
Authors
- Sally Ibrahim
- J Douglas Hudson
- Anne Marie Morse (ORCID: https://orcid.org/0000-0003-4494-0195)
- Brian Abaluck
- Jordan Dubow
- John Harsh (ORCID: https://orcid.org/0000-0001-6532-9278)
- Paula K. Schweitzer
- Emmanuel Mignot (ORCID: https://orcid.org/0000-0002-6928-5310)
- Bruce Corser
- Jennifer Gudeman
- Adrian Santamaria
- Akinyemi O. Ajayi
- Thomas Stern
- Katie Lancaster
- Asim Roy
Institutions
- Geisinger Medical Center (US)
- University Hospitals of Cleveland (US)
- St. Luke's Hospital (US)
- Futures Group (United States) (US)
- Center for Independent Living (US)
- Sleep Management Institute (US)
- New Century Pharmaceuticals (United States) (US)
- Future Search Trials (US)
- Comprehensive Cardiovascular (US)
- Colorado Sleep Institute (US)
- Geisinger Commonwealth School of Medicine (US)
- National Patient Safety Foundation (US)
- Stanford University (US)
Publication Details
- Journal
- Sleep Medicine X
- Published
- 2024-08-15
- DOI
- https://doi.org/10.1016/j.sleepx.2024.100122
- Citations
- 6
- Primary Topic
- Behavioral Health and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 2.46
Funders
- Ariad Pharmaceuticals
- Citrus Research Board
- Johnson and Johnson